Drug Profile
Research programme: microbiome therapeutics - Second Genome
Latest Information Update: 15 Aug 2021
Price :
$50
*
At a glance
- Originator Second Genome
- Developer Oregon State University; Second Genome; Stanford University School of Medicine
- Class Behavioural disorder therapies
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autistic disorder
Most Recent Events
- 10 Aug 2021 Pharmacodynamics data from a preclinical study in Autistic disorder released by Second Genome
- 01 Aug 2021 Preclinical trials in Autistic disorder in USA (unspecified route), before August 2021
- 16 Apr 2019 Second Genome receives phase II SBIR grant for microbiome therapeutics development for Autism spectrum disorders